Saturday, January 19, 2019

Lilly cancer drug fails key trial, will no longer be prescribed

Leave a Comment
Eli Lilly and Co said on Friday that its cancer treatment Lartruvo, which had won conditional approval, failed to improve patient survival in a long-term confirmatory study and will no longer be prescribed, driving the drugmaker's shares down nearly 3 percent.


from Reuters: U.S. https://reut.rs/2R28q8M
If You Enjoyed This, Take 5 Seconds To Share It

0 comments:

Post a Comment